June 19, 2020 -The National Medical Products Administration approved the IND application of  Abogen’s mRNA-based COVID-19 vaccine, which is also the first mRNA-based drug approved for clinical trials in China.

About Abogen

Abogen is a clinical-stage biotechnology company focused on advancing mRNA-based therapeutics for the treatment of cancer and other infectious diseases. Since its establishment in January 2019, Abogen has developed its own mRNA technology platform and proprietary delivery system which empowers the development of a series of drug product candidates including vaccines for infectious diseases and therapies for cancer.